Yahoo · Jul 7, 2026
New Strong Sell Stocks for July 7th
AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
DR
NASDAQ · DRTSW
Alpha Tau Medical Ltd.
Healthcare · Biotechnology
$3.74
Down-$0.15 (-3.86%)
Updated Aug 15, 2026, 8:54 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 31.51M
- P/E ratio
- -10.28
- Dividend yield
- 0.00%
- 52-week range
- $0.72 – $4.28
- Volume
- 59.15K
- Avg. volume
- 15.87K
Price performance
DRTSW price history
1M range · 21 trading sessions · Daily adjusted prices
DRTSW closed at $3.74 after 21 trading sessions, down 0.27% for the selected period.
- Last close
- $3.74
- Period change
- -0.27%
- Period low
- $2.29
- Period high
- $3.89
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $3.99 | $3.99 | $3.60 | $3.74 | 59.15K |
| Aug 13, 2026 | $3.53 | $4.00 | $3.53 | $3.89 | 68.51K |
| Aug 12, 2026 | $3.77 | $3.85 | $3.35 | $3.57 | 36.58K |
| Aug 11, 2026 | $3.31 | $3.89 | $3.31 | $3.89 | 113.29K |
| Aug 10, 2026 | $3.50 | $3.60 | $3.32 | $3.46 | 43.42K |
| Aug 7, 2026 | $3.34 | $3.405 | $3.19 | $3.40 | 10.87K |
| Aug 6, 2026 | $3.40 | $3.59 | $3.23 | $3.23 | 21.09K |
| Aug 5, 2026 | $3.30 | $3.48 | $3.28 | $3.37 | 21.14K |
| Aug 4, 2026 | $2.84 | $3.31 | $2.84 | $3.30 | 32.51K |
| Aug 3, 2026 | $2.42 | $2.6799 | $2.42 | $2.58 | 12.59K |
| Jul 31, 2026 | $2.795 | $2.795 | $2.46 | $2.69 | 12.16K |
| Jul 30, 2026 | $2.465 | $2.77 | $2.38 | $2.70 | 18.77K |
| Jul 29, 2026 | $2.65 | $2.65 | $2.22 | $2.29 | 19.64K |
| Jul 28, 2026 | $3.11 | $3.11 | $2.43 | $2.55 | 42.97K |
| Jul 27, 2026 | $3.36 | $3.40 | $2.95 | $2.97 | 12.08K |
| Jul 24, 2026 | $3.62 | $3.62 | $3.11 | $3.18 | 30K |
| Jul 23, 2026 | $3.45 | $3.71 | $3.45 | $3.54 | 4.14K |
| Jul 22, 2026 | $3.65 | $3.74 | $3.30 | $3.30 | 32.33K |
| Jul 21, 2026 | $4.00 | $4.00 | $3.44 | $3.51 | 106.6K |
| Jul 20, 2026 | $4.00 | $4.00 | $3.51 | $3.76 | 85.43K |
| Jul 17, 2026 | $2.93 | $3.90 | $2.70 | $3.75 | 119.81K |
Latest DRTSW news
The latest Smart Investors Daily articles mentioning DRTSW.
Stock researchCompany · Overview
DRTSW research
Overview
Company profile and research snapshot.
Company profile
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Jul 2, 2026
New Strong Sell Stocks for July 2nd
DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
Yahoo · Apr 27, 2026
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
- Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world’s largest and most prestigious medical oncology conference - - Pooled analysis combines safety and efficacy data from 58 patients across three prospective clinical studies conducted at centers in Canada and Israel - - Acceptance of abstract comes in the same year as presentations at the ASCO Gastrointestinal Cancers Symposium and at Digestive Disease Week (DDW), reflecting growing interest within t
Yahoo · Apr 23, 2026
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to 40 patients - - Study explores Alpha DaRT combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma - - This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest u
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
